Pfizer weighs job cuts in Korea; CEO Soriot beefs up AZ stake with £3M share purchase; Sanofi eyes expansion in England;

@FiercePharma: China's Ascletis gets Taiwan nod for PhII trial of interferon-free HCV candidate. FiercePharmaAsia article | Follow @FiercePharma

@CarlyHFierce: ICYMI: AstraZeneca sales team revving up for new Brilinta marketing push. More | Follow @CarlyHFierce

> Pfizer ($PFE) is eyeing its operations in South Korea for job cuts, with plans to offer early retirement to a range of employees in the region. Report

> AstraZeneca ($AZN) CEO Pascal Soriot has plowed an additional £3 million of his money into AstraZeneca stock, adding more than 76,000 shares to his holdings. Report

> Sanofi ($SNY) has filed for permission to expand its production facilities in Cheshire, England, with additional manufacturing, warehouse and lab space. Report

> Sanofi's Prague-based generics unit Zentiva produces more than half the company's generics products, delivering drugs to countries in Europe, Asia, Africa and the Middle East. Report

Medical Device News

@FierceMedDev: Updated w/ company comment: Merck, Daktari collaborating on hep C diagnostic. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: HeartWare looks diversify into mitral valve repair with $929M purchase of Valtech Cardio. Article | Follow @VarunSaxena2

@EmilyWFierce: European pharma lobby says 'non' to French funding for off-label Avastin. ICYMI fron FiercePharma | Follow @EmilyWFierce

> Stratasys launches 3-D printer for production of dental devices. Story

> Valeant to buy microsurgery tools company Synergetics for up to $190M. Article

Biotech News

@FierceBiotech: The 2015 Fierce 15 will be announced in a few weeks. Celebrate the winners with us in October at #BIF15. More | Follow @FierceBiotech

@JohnCFierce: Looking forward to an upcoming panel discussion on organ-on-a-chip tech. And you can't beat the price. More | Follow @JohnCFierce

@DamianFierce: Look at this idiot thing I wrote last year. Article | Follow @DamianFierce

> Booming Gilead gets a blueprint for a big new HQ addition. Report

> Regeneron's genetics team IDs a candidate for ultra-rare bone disease. Story

> Celyad set to scale up China-focused R&D activities after linking with Medisun. More

> Acadia finally delivers long-delayed application for 'breakthrough' Parkinson's drug. Article

Vaccines News

> Daiichi Sankyo inks deal to market AstraZeneca's FluMist in Japan. More

> Cornell grad looks to change the way parents remember vaccine schedules. Report

> GlaxoSmithKline signs on LimmaTech for vaccine R&D. Story

> NHS meningitis B vaccination scheme begins in U.K. Item

> BiondVax pairs with NIAID to test universal flu vaccine in U.S. PhII. Article

CRO News

> PPD partners up to better track trial events. News

> WuXi looks to Japan for manufacturing growth. Report

> BioClinica opens an app umbrella to unite researchers. More

> Chinese drugmaker trades $200M for CDMO Cytovance. Story

> AMRI signs on to help Saneca develop opium-based drugs. Article

Pharma Manufacturing News

> Sun gets direct line to poppy production with buyout of GSK opiates biz. Report

> Lannett manufacturing capacity balloons to 522,000 sq. ft. in short order. Story

> China poaches Indian scientists to build formulation expertise. News

> Novo building huge warehouse to support production expansion. Item

> Sun recalls yet another med made at troubled Halol plant. Report

Pharma Asia News

> Pharma market bets on ASEAN in focus ahead of economic pact. Story

> HK's Medisun, Belgium's Celyad revise C-Cure pact for Greater China. Item

> China's Ascletis gets Taiwan nod for PhII trial of interferon-free HCV candidate. Report

> GSK hep B supplies to Japan hit by Tianjin explosion. Story

> Abbott touts Japan drug-eluting Absorb stent trial results, but no approval timeline. Article

And Finally... Scientists dug into a range of biologic meds for rheumatoid arthritis to find that there was a higher risk of infections in Medicare patients who'd switched to Enbrel (etanercept) from another biologic compared with Orencia (abatacept). Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.